Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jushi Holdings Inc. (JUSHF)
USD0.46
-0.01 (-3.06%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
301 Yamato Road 33431
Boca Raton, FL, US
Boca Raton, FL, US
CEO
James Cacioppo
Website
jushico.com
IPO
2019-06-18
CIK 1909747 ISIN CA48213Y1079
Also trades on
Canadian Securities Exchange · JUSH.CN (CAD)
Other OTC · JUSHF (USD)
Description
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for the medical and adult-use markets in the United States. The company offers flowers, extracts, concentrates, edibles, pre-rolls, infused blunts, cannabis-infused gummies and chocolates, tinctures, capsules, softgels, and topical products, as well as vaporization devices and cartridges under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, and Sèche brands. It also engages in the sale of bulk raw materials to third parties. In addition, the company operates medical cannabis dispensaries under the Beyond Hello, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. Jushi Holdings Inc. was founded in 2018 and is headquartered in Boca Raton, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.46
-0.01 (-3.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
197.4K
Beta
0.87
Float Shares
165.94M
Free Float %
83.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.85% | -5.66% | -5.68% | -1.30% | -7.41% | -20.63% | +41.23% | +7.76% | -91.61% | -80.11% | -80.11% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.46
Low
1.50
+223.6%
Consensus
1.93
+316.4%
Median
1.93
+315.3%
High
2.35
+407.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 4 |
2.15
+363.8%
|
Quality scores
Altman Z-Score
-1.25
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.1% Q1'26: +4.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-40.0% Q1'26: -15.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-19.8% Q1'26: +13.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.9% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×7.58× Q1'26: 12.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.23M
est: 7.44M (+37.6%)
|
80.77M
est: 63.40M (+27.4%)
|
207.55M
est: 164.71M (+26.0%)
|
273.02M
est: 212.59M (+28.4%)
|
269.45M
est: 201.06M (+34.0%)
|
257.53M
est: 255.27M (+0.9%)
|
262.91M
est: 263.60M (-0.3%)
|
274.35M
274.10M – 274.60M
+4.1% YoY
|
326.58M
311.22M – 341.93M
+19.0% YoY
|
399.05M
379.82M – 417.59M
+22.2% YoY
|
383.60M
365.12M – 401.43M
-3.9% YoY
|
416.10M
396.05M – 435.44M
+8.5% YoY
|
| EBITDA |
-21.83M
est: -1.05M (-1,981.3%)
|
-181.90M
est: -8.94M (-1,933.6%)
|
86.37M
est: -23.24M (+471.7%)
|
-121.65M
est: -29.99M (-305.6%)
|
30.42M
est: -28.36M (+207.2%)
|
50.72M
est: 26.06M (+94.7%)
|
38.69M
est: 26.91M (+43.8%)
|
28.00M
27.98M – 28.03M
+4.1% YoY
|
33.33M
31.77M – 34.90M
+19.0% YoY
|
40.73M
38.77M – 42.63M
+22.2% YoY
|
39.16M
37.27M – 40.97M
-3.9% YoY
|
42.47M
40.43M – 44.45M
+8.5% YoY
|
| EBIT |
-24.06M
est: -1.57M (-1,435.7%)
|
-186.33M
est: -13.36M (-1,294.8%)
|
-16.70M
est: -34.71M (+51.9%)
|
-148.14M
est: -44.79M (-230.7%)
|
5.88M
est: -42.36M (+113.9%)
|
20.84M
est: 4.57M (+355.7%)
|
7.70M
est: 4.72M (+63.0%)
|
4.91M
4.91M – 4.92M
+4.1% YoY
|
5.85M
5.57M – 6.12M
+19.0% YoY
|
7.15M
6.80M – 7.48M
+22.2% YoY
|
6.87M
6.54M – 7.19M
-3.9% YoY
|
7.45M
7.09M – 7.80M
+8.5% YoY
|
| Net Income |
-30.77M
|
-211.87M
est: -110.15M (-92.3%)
|
20.08M
est: 2.34M (+757.5%)
|
-202.32M
est: -86.77M (-133.2%)
|
-66.30M
est: -51.39M (-29.0%)
|
-48.78M
est: -42.80M (-14.0%)
|
-68.59M
est: -56.12M (-22.2%)
|
-34.58M
-34.86M – -34.31M
+38.4% YoY
|
-24.40M
-31.37M – -15.69M
+29.4% YoY
|
-13.66M
-14.49M – -12.81M
+44.0% YoY
|
-11.71M
-12.42M – -10.98M
+14.3% YoY
|
-3.90M
-4.14M – -3.66M
+66.7% YoY
|
| SGA |
33.33M
est: 3.49M (+855.0%)
|
51.65M
est: 29.76M (+73.5%)
|
112.82M
est: 77.32M (+45.9%)
|
156.17M
est: 99.79M (+56.5%)
|
84.10M
est: 94.38M (-10.9%)
|
79.08M
est: 92.16M (-14.2%)
|
78.26M
est: 95.16M (-17.8%)
|
99.04M
98.95M – 99.13M
+4.1% YoY
|
117.90M
112.36M – 123.44M
+19.0% YoY
|
144.06M
137.12M – 150.76M
+22.2% YoY
|
138.48M
131.81M – 144.92M
-3.9% YoY
|
150.22M
142.98M – 157.20M
+8.5% YoY
|
| EPS |
-0.37
|
-1.94
est: -0.56 (-243.7%)
|
0.12
est: 0.01 (+900.0%)
|
-1.07
est: -0.44 (-140.7%)
|
-0.33
est: -0.26 (-25.3%)
|
-0.25
est: -0.22 (-14.0%)
|
-0.35
est: -0.29 (-21.7%)
|
-0.18
-0.18 – -0.18
+38.4% YoY
|
-0.13
-0.16 – -0.08
+29.4% YoY
|
-0.07
-0.07 – -0.07
+44.0% YoY
|
-0.06
-0.06 – -0.06
+14.3% YoY
|
-0.02
-0.02 – -0.02
+66.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.55M
OE per share TTM
-0.05
Owner's Yield
-10.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
83.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | James A. Cacioppo | 40.03M | 17.81% | 16.90M | 23.13M | 16.90M | 10.00 | IN | United States | 2023-09-01 | ↗ |
| 2 | Denis Arsenault | 24.38M | 11.43% | 24.38M | — | 24.38M | — | IN | Canadian | 2023-09-01 | ↗ |
| 3 | Nomura Global Financial Products, Inc. | 13.59M | 6.90% | — | 13.59M | — | 13.59M | BD | Japan | 2024-02-14 | ↗ |
| 4 | Nomura Holdings, Inc. | 13.59M | 6.90% | — | 13.59M | — | 13.59M | HC | Japan | 2024-02-14 | ↗ |
| 5 | One East Partners L.P. | 6.88M | 3.43% | 6.88M | — | 6.88M | 10.00 | PN | Delaware | 2023-09-01 | ↗ |
| 6 | OEP Opportunities, L.P. | 6.50M | 3.24% | 6.50M | — | 6.50M | 10.00 | PN | Delaware | 2023-09-01 | ↗ |
| 7 | One East Capital Advisors, LP | 4.34M | 2.17% | 4.34M | — | 4.34M | 10.00 | PN | Delaware | 2023-09-01 | ↗ |
| 8 | Serpentine Capital Management II, LLC | 3.72M | 1.86% | 3.72M | — | 3.72M | 10.00 | PN | Delaware | 2023-09-01 | ↗ |
| 9 | JAC Serpentine LLC | 900.0K | 0.46% | 900.0K | — | 900.0K | 10.00 | OO | Nevada | 2023-09-01 | ↗ |
| 10 | ST 2 LLC | 795.5K | 0.40% | 795.5K | — | 795.5K | 10.00 | PN | Florida | 2023-09-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Pure US Cannabis ETF MSOS | 1.02% | 9.32M | 0.81% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.22
Neutral
Ratio by volume
0.77
Neutral
Buys
11
Sells
9
Shares acquired
5.99M
Shares disposed
7.81M
Cash buys
—
Cash sales
—
Net activity
-1,819,821
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-17 | Wafford Bill | Director | A-Award | A | Stock Option (right to buy) | 101,429 | 0.55 | 55.8K | 101,429 | — | ↗ |
| 2023-12-17 | Monroe Stephen | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 0.55 | 44.0K | 80,000 | — | ↗ |
| 2023-12-17 | MOSIER MICHELLE O | Officer | A-Award | A | Warrant (right to buy) | 200,000 | 0.55 | 110.0K | 200,000 | — | ↗ |
| 2023-12-17 | Lebowitz Tobi | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 0.55 | 165.0K | 300,000 | — | ↗ |
| 2023-12-17 | HAHN MARINA | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.55 | 22.0K | 40,000 | — | ↗ |
| 2023-12-17 | Cross Benjamin | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 0.55 | 44.0K | 80,000 | — | ↗ |
| 2023-12-17 | Cacioppo James | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 3,000,000 | 0.55 | 1.65M | 3,000,000 | — | ↗ |
| 2023-12-17 | Barack Louis Jon | Officer | A-Award | A | Stock Option (right to buy) | 1,000,000 | 0.55 | 550.0K | 1,000,000 | — | ↗ |
| 2023-11-17 | Monroe Stephen | Director | D-Return | D | Stock Option (right to buy) | 60,000 | 3.91 | 234.6K | 258,952 | — | ↗ |
| 2023-11-17 | MOSIER MICHELLE O | Officer | D-Return | D | Warrant (right to buy) | 200,000 | 1.75 | 350.0K | 200,000 | — | ↗ |
| 2023-11-17 | Lebowitz Tobi | Officer | D-Return | D | Stock Option (right to buy) | 165,000 | 3.91 | 645.2K | 890,000 | — | ↗ |
| 2023-11-17 | HAHN MARINA | Director | D-Return | D | Stock Option (right to buy) | 20,000 | 3.91 | 78.2K | 180,000 | — | ↗ |
| 2023-11-17 | Cross Benjamin | Director | D-Return | D | Stock Option (right to buy) | 60,000 | 3.91 | 234.6K | 180,000 | — | ↗ |
| 2023-11-17 | Cacioppo James | Director / Officer / 10% Owner | D-Return | D | Stock Option (right to buy) | 3,000,000 | 3.91 | 11.73M | 0 | — | ↗ |
| 2023-11-17 | Barack Louis Jon | Officer | D-Return | D | Stock Option (right to buy) | 1,000,000 | 3.91 | 3.91M | 3,893,000 | — | ↗ |
| 2023-09-12 | MOSIER MICHELLE O | Officer | P-Purchase | A | Subordinate Voting Shares | 30,567 | 0.70 | 21.4K | 97,067 | — | ↗ |
| 2023-09-07 | MOSIER MICHELLE O | Officer | P-Purchase | A | Subordinate Voting Shares | 66,500 | 0.75 | 49.9K | 66,500 | — | ↗ |
| 2023-09-01 | Cacioppo James | Director / Officer / 10% Owner | A-Award | A | Warrant (right to buy) | 551,471 | 0.68 | 375.0K | 32,665,551 | — | ↗ |
| 2023-06-27 | Cacioppo James | Director / Officer / 10% Owner | D-Return | D | Warrant (right to buy) | 719,080 | 2.09 | 1.50M | 31,395,000 | — | ↗ |
| 2023-06-27 | Arsenault Denis J. | 10% Owner | P-Purchase | A | Warrant (right to buy) | 3,452,595 | 1.00 | 3.45M | 16,702,595 | — | ↗ |
| 2023-05-17 | Wafford Bill | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.48 | 60.3K | 225,806 | — | ↗ |
| 2023-05-17 | Upshaw Nichole Lee | Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 0.48 | 217.2K | 1,420,000 | — | ↗ |
| 2023-05-17 | Monroe Stephen | Director | A-Award | A | Stock Option (right to buy) | 125,000 | 0.48 | 60.3K | 318,952 | — | ↗ |
| 2023-05-17 | Lebowitz Tobi | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 0.48 | 144.8K | 1,355,000 | — | ↗ |
| 2023-05-17 | HAHN MARINA | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.48 | 48.3K | 200,000 | — | ↗ |
| 2023-05-17 | Cross Benjamin | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.48 | 48.3K | 360,000 | — | ↗ |
| 2023-05-17 | Barack Louis Jon | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 0.48 | 289.6K | 4,893,000 | — | ↗ |
| 2023-02-06 | MOSIER MICHELLE O | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.61 | 122.0K | 400,000 | — | ↗ |
| 2022-12-09 | MOSIER MICHELLE O | Officer | — | D | Warrant (right to buy) | 200,000 | 1.75 | 350.0K | — | — | ↗ |
| 2022-12-09 | Cacioppo James | Officer | A-Award | A | Stock Option (right to buy) | 3,000,000 | 1.75 | 5.25M | 32,114,080 | — | ↗ |
| 2022-12-08 | Cacioppo James | Officer | A-Award | A | Warrant (right to buy) | 719,080 | 2.09 | 1.50M | 29,114,080 | — | ↗ |
| 2022-12-07 | Arsenault Denis J. | Director | A-Award | A | Warrant (right to buy) | 3,452,595 | 0.00 | — | 16,702,595 | — | ↗ |
| 2022-12-01 | Upshaw Nichole Lee | Officer | — | D | Subordinate Voting Shares | 0 | 0.00 | — | 125,448 | — | ↗ |
| 2022-10-10 | Wafford Bill | Director | — | D | Stock Option (right to buy) | 100,806 | 1.91 | 192.5K | 0 | — | ↗ |
| 2022-09-26 | Arsenault Denis J. | 10% Owner | — | D | Subordinate Voting Shares | 0 | 0.00 | — | 7,677,899 | — | ↗ |
| 2022-08-29 | Lebowitz Tobi | Officer | — | D | Stock Option (right to buy) | 170,000 | 1.93 | 328.1K | 0 | — | ↗ |
| 2022-08-12 | Monroe Stephen | Director | — | D | Subordinate Voting Shares | 0 | 0.00 | — | 153,684 | — | ↗ |
| 2022-08-12 | HAHN MARINA | Director | — | D | Stock Option (right to buy) | 80,000 | 1.93 | 154.4K | 0 | — | ↗ |
| 2022-08-12 | Garcia-Berg Leonardo | Officer | — | D | Stock Option (right to buy) | 170,000 | 1.93 | 328.1K | 0 | — | ↗ |
| 2022-08-12 | Cross Benjamin | Director | — | D | Subordinate Voting Shares | 0 | 0.00 | — | 239,080 | — | ↗ |
| 2022-08-12 | Cacioppo James | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 3,000,000 | 1.93 | 5.79M | 0 | — | ↗ |
| 2022-08-12 | Cabral James | Officer | — | D | Subordinate Voting Shares | 0 | 0.00 | — | 106,415 | — | ↗ |
| 2022-08-12 | Barack Louis Jon | Officer | — | D | Stock Option (right to buy) | 830,000 | 1.93 | 1.60M | 0 | — | ↗ |
| 2022-08-12 | Adderton Peter Alan | Director | — | D | Stock Option (right to buy) | 80,000 | 1.93 | 154.4K | 0 | — | ↗ |
| 2022-07-28 | Upshaw Nichole Lee | Officer | — | D | Stock Option (right to buy) | 320,000 | 1.93 | 617.6K | — | — | ↗ |
| 2022-07-01 | Monroe Stephen | Director | — | D | Stock Option (right to buy) | 60,000 | 3.91 | 234.6K | 0 | — | ↗ |
| 2022-07-01 | HAHN MARINA | Director | — | D | Stock Option (right to buy) | 20,000 | 3.91 | 78.2K | 0 | — | ↗ |
| 2022-07-01 | Cross Benjamin | Director | — | D | Stock Option (right to buy) | 60,000 | 3.91 | 234.6K | 0 | — | ↗ |
| 2022-07-01 | Adderton Peter Alan | Director | — | D | Stock Option (right to buy) | 60,000 | 3.91 | 234.6K | 0 | — | ↗ |
| 2022-04-17 | Lebowitz Tobi | Officer | — | D | Stock Option (right to buy) | 250,000 | 2.00 | 500.0K | 0 | — | ↗ |
| 2022-04-17 | Cacioppo James | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 2,385,000 | 2.00 | 4.77M | 0 | — | ↗ |
| 2022-04-17 | Barack Louis Jon | Officer | — | D | Stock Option (right to buy) | 793,000 | 2.00 | 1.59M | 0 | — | ↗ |
| 2021-12-31 | Monroe Stephen | Director | — | D | Stock Option (right to buy) | 13,952 | 5.71 | 79.7K | 0 | — | ↗ |
| 2020-07-11 | Cross Benjamin | Director | — | D | Warrant (right to buy) | 120,000 | 1.25 | 150.0K | 0 | — | ↗ |
| 2020-07-11 | Cacioppo James | Director / Officer / 10% Owner | — | I | Warrant (right to buy) | 900,000 | 1.25 | 1.13M | 0 | — | ↗ |
| 2020-06-19 | Arsenault Denis J. | 10% Owner | — | D | Warrant (right to buy) | 1,500,000 | 1.25 | 1.88M | 0 | — | ↗ |
| 2019-06-10 | Cacioppo James | Director / Officer / 10% Owner | — | I | Warrant (right to buy) | 1,400,000 | 1.00 | 1.40M | 0 | — | ↗ |
| 2019-06-10 | Barack Louis Jon | Officer | — | D | Warrant (right to buy) | 1,500,000 | 1.00 | 1.50M | 0 | — | ↗ |
| 2019-04-17 | Arsenault Denis J. | 10% Owner | — | D | Warrant (right to buy) | 500,000 | 2.00 | 1.00M | 0 | — | ↗ |
| 2018-09-27 | Cacioppo James | Director / Officer / 10% Owner | — | I | Warrant (right to buy) | 175,000 | 1.50 | 262.5K | 0 | — | ↗ |
| 2018-02-13 | Arsenault Denis J. | 10% Owner | — | D | Warrant (right to buy) | 2,750,000 | 0.50 | 1.38M | 0 | — | ↗ |
| 2018-02-10 | Arsenault Denis J. | 10% Owner | — | D | Warrant (right to buy) | 4,000,000 | 1.00 | 4.00M | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
5.6K
Shares Outstanding
199.70M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | James Cacioppo Chief Executive Officer | 1.05M | 1.80M | — | — | — | 19.4K | 2.87M | 0.00% | ↗ |
| 2 | 2025 | Louis Jonathan Barack President, Chief Revenue Officer and Corporate Secretary | 450.0K | 360.0K | — | 188.9K | — | 35.5K | 1.03M | 18.26% | ↗ |
| 3 | 2025 | Michelle Mosier Chief Financial Officer and Chief Accounting Officer | 425.0K | 212.5K | — | 113.3K | — | 18.8K | 769.6K | 14.72% | ↗ |
| 4 | 2024 | James Cacioppo Chief Executive Officer | 850.0K | 1.62M | — | 1.03M | — | 54.8K | 3.55M | 28.93% | ↗ |
| 5 | 2024 | Louis Jonathan Barack President, Chief Revenue Officer and Corporate Secretary | 414.6K | 265.3K | — | 215.2K | — | 30.1K | 925.2K | 23.26% | ↗ |
| 6 | 2024 | Todd West Chief Operating Officer | 300.0K | 133.3K | — | 465.6K | — | 11.3K | 910.2K | 51.15% | ↗ |
| 7 | 2024 | Michelle Mosier Chief Financial Officer and Chief Accounting Officer | 414.6K | 165.8K | — | 112.3K | — | 17.4K | 710.2K | 15.82% | ↗ |
| 8 | 2023 | James Cacioppo Chief Executive Officer | 850.0K | 1.58M | — | 1.11M | — | 20.7K | 3.57M | 31.17% | ↗ |
| 9 | 2023 | Louis Jon Barack President | 400.0K | 120.0K | — | 388.1K | — | 23.6K | 931.7K | 41.65% | ↗ |
| 10 | 2023 | Michelle Mosier Chief Financial Officer | 383.3K | 125.0K | — | 235.8K | — | 9.3K | 753.4K | 31.30% | ↗ |
| 11 | 2022 | James Cacioppo Chief Executive Officer | 750.0K | 1.00M | — | 6.72M | — | 34.0K | 8.50M | 79.01% | ↗ |
| 12 | 2022 | Leonardo Garcia-Berg Former Chief Operations Officer | 330.0K | — | — | 2.32M | — | 25.0K | 2.67M | 86.73% | ↗ |
| 13 | 2022 | Louis Jon Barack President | 400.0K | — | — | 1.25M | — | 25.0K | 1.68M | 74.64% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Anthony Cacioppo | Founder, Chairman & Chief Executive Officer | 3M | male |
| Louis Jonathan Barack | Founder, President, Chief Revenue Officer & Corporate Secretary | 845.6K | male |
| Michelle O. Mosier | Chief Financial Officer & Chief Accounting Officer | 656.3K | female |
| Trenton Woloveck | Co-Chief Strategy Director | 544.2K | male |
| Harris Shain | Co-Chief Strategy Director | 544.2K | male |
| Lisa Forman | Vice President of Investor Relations | — | female |
| Matthew Leeth | Chief Regulatory Director & Senior Executive Counsel | — | male |
| Ian Farrell | Vice President of Compliance | — | male |
| Toya Bellamy-Lockhart | Executive Vice President of Human Resources | — | female |
| Andreas Neumann | Chief Creative Director | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JUSHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
